Boehringer Ingelheim has announced that China's National Medical Products Administration (NMPA) has approved JASCAYD (nerandomilast) as an oral treatment option for idiopathic pulmonary fibrosis (IPF) in adult patients.

This approval comes only two weeks after being approved by the Food and Drug Administration (FDA) in the United States.

“IPF has long been a difficult disease to diagnose and manage, marked by a progressive decline in lung function and a profound impact on patients’ daily lives,” said Professor Xu Zuojun, chief physician of the Department of Respiratory and Critical Care Medicine of Peking Union Medical College Hospital. “As the first innovative therapy in over a decade to achieve the primary endpoint in a Phase III clinical trial, nerandomilast not only demonstrates sig

See Full Page